TAVI – Medxy AI

Rethinking Hemodynamics in Aortic Stenosis: The Paradoxical Normal-Flow, Low-Ejection Fraction Phenotype and Post-TAVI Outcomes

By MedXY 01/22/2026

A substudy of the COMPARE-TAVI 1 trial identifies a unique NF-LEF phenotype in 10.7% of aortic stenosis patients. Despite reduced LVEF, these patients maintain normal flow through eccentric remodeling and achieve clinical improvements post-TAVI comparable to those with preserved ejection fractions.

Cardiology news OB/GYN & Women’s Health

TAVI vs. SAVR in Women: RHEIA Trial Reveals Distinctive Echocardiographic Advantages for Both Approaches

By MedXY 01/22/2026

The RHEIA trial substudy compares echocardiographic outcomes between TAVI and SAVR in women. While SAVR offers superior LVH regression and lower gradients, TAVI demonstrates significant benefits in preserving right ventricular function and preventing the progression of cardiac damage stages.

Cardiology Neurology news

Routine Cerebral Embolic Protection Fails to Mitigate Stroke or Cognitive Decline in TAVI: Results from the BHF PROTECT-TAVI Trial

By MedXY 01/18/2026

The landmark BHF PROTECT-TAVI trial reveals that cerebral embolic protection (CEP) does not reduce periprocedural stroke or cognitive impairment following TAVI. This large-scale study challenges the routine use of embolic filters, suggesting that neurological outcomes are influenced by factors beyond intraprocedural debris capture.

Cardiology news

FFR-Guided Revascularization Significantly Reduces 12-Month MACCE in TAVI Patients: The FAITAVI Trial

By MedXY 01/03/2026

The FAITAVI trial demonstrates that physiology-guided PCI using FFR significantly reduces major adverse cardiac events, particularly mortality, compared to angiography-guided PCI in elderly patients undergoing TAVI with intermediate coronary lesions.

Cardiology news

Percutaneous Strategy (TAVI + FFR-guided PCI) Outperforms SAVR + CABG at 1 Year in Patients ≥70 with Severe Aortic Stenosis and Complex Coronary Disease: Results of the TCW Randomised Trial

By MedXY 11/11/2025

The TCW trial randomized 172 patients ≥70 years with severe aortic stenosis and complex coronary disease to FFR-guided PCI plus TAVI versus SAVR plus CABG. At 1 year the percutaneous strategy met non-inferiority and demonstrated superiority for a composite endpoint driven by lower mortality and life‑threatening bleeding.

Cardiology news

Long-Term Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement: A Meta-Analysis of Time-to-Event Data

By MedXY 10/12/2025

This meta-analysis evaluates 5-year outcomes comparing TAVI and SAVR across risk profiles, revealing early advantages with TAVI that level off long-term, with no significant difference at 5 years.

Cardiology Clinical Updates news Specialties

Head-to-Head Comparison of SAPIEN 3 and Myval Transcatheter Heart Valves in TAVI: Insights from the COMPARE-TAVI 1 Trial

By MedXY 09/07/2025

The COMPARE-TAVI 1 trial demonstrates non-inferiority of Myval transcatheter heart valves compared to SAPIEN 3 THVs at 1-year post-TAVI for a composite clinical endpoint in severe aortic stenosis patients.

Cardiology Clinical Updates news Specialties

Minimizing Anesthesia in Transcatheter Aortic Valve Implantation: Insights from the DOUBLE-CHOICE Trial

By MedXY 09/07/2025

The DOUBLE-CHOICE randomized trial demonstrates non-inferiority of isolated local anesthesia versus conscious sedation in transfemoral TAVI, suggesting a safe minimalist anesthesia strategy with potential trade-offs in patient comfort.

Cardiology news Specialties

Cerebral Embolic Protection and Cognitive Outcomes After TAVI: Insights from the BHF PROTECT-TAVI Trial

By MedXY 09/06/2025

The BHF PROTECT-TAVI randomized trial found no cognitive benefit from using cerebral embolic protection devices during transcatheter aortic valve implantation, despite their theoretical role in mitigating embolic brain injury.

Cardiology Neurology news Specialties

Cerebral Embolic Protection Fails to Preserve Cognitive Function After TAVI: Insights from the BHF PROTECT-TAVI Trial

By MedXY 09/06/2025

The BHF PROTECT-TAVI randomized trial reveals that cerebral embolic protection (CEP) devices do not prevent cognitive decline following transcatheter aortic valve implantation (TAVI), challenging assumptions about their neuroprotective benefits.

Cardiology Medical News news Specialties

TAVI vs SAVR at Low–Intermediate Risk: What the New Individual‑Patient Meta‑Analysis Means for Practice

By MedXY 08/31/2025

A patient‑level meta‑analysis of randomized trials finds transcatheter aortic valve implantation (TAVI) reduces 1‑year risk of death or stroke versus surgical AVR in low– to intermediate‑risk patients—informing patient selection, heart‑team decisions, and follow‑up priorities.

Cardiology Clinical Updates news Specialties

Percutaneous versus Surgical Approaches in Aortic Stenosis with Complex Coronary Disease: TCW Trial Insights

By MedXY 08/02/2025

The TCW trial demonstrates that FFR-guided PCI plus TAVI is non-inferior and even superior to SAVR plus CABG in elderly patients with severe aortic stenosis and complex coronary artery disease.

Cardiology Clinical Updates news Specialties

Routine Use of Cerebral Embolic Protection in TAVI: Evidence, Outcomes, and Clinical Implications

By MedXY 08/01/2025

Large-scale trials show that routine cerebral embolic protection during TAVI does not significantly reduce early stroke rates, though selective benefits in major stroke and secondary outcomes may exist.